Literature DB >> 21719892

Azathioprine in the management of enteropathy in cystic fibrosis.

Hui-Leng Tan1, Neil Shah, Ranjan Suri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21719892      PMCID： PMC3128164          DOI： 10.1258/jrsm.2011.s11107

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  15 in total

1.  Inflammation of the cystic fibrosis mouse small intestine.

Authors:  Oxana Norkina; Simran Kaur; Donna Ziemer; Robert C De Lisle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-01-22       Impact factor: 4.052

2.  THE INTESTINAL LESIONS IN CYSTIC FIBROSIS OF THE PANCREAS.

Authors:  T S THOMAIDIS; J B AREY
Journal:  J Pediatr       Date:  1963-09       Impact factor: 4.406

3.  LIGHT AND ELECTRON MICROSCOPIC EXAMINATION OF THE SMALL BOWEL OF CHILDREN WITH CYSTIC FIBROSIS.

Authors:  H B FREYE; S M KURTZ; A SPOCK; M P CAPP
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

4.  Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients.

Authors:  V Raia; L Maiuri; G de Ritis; B de Vizia; L Vacca; R Conte; S Auricchio; M Londei
Journal:  Pediatr Res       Date:  2000-03       Impact factor: 3.756

5.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.

Authors:  A G Fraser; T R Orchard; D P Jewell
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 6.  Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

Authors:  Richard B Gearry; Murray L Barclay
Journal:  J Gastroenterol Hepatol       Date:  2005-08       Impact factor: 4.029

Review 7.  Intestinal dysmotility in inflammatory bowel disease: mechanisms of the reduced activity of smooth muscle contraction.

Authors:  Hiroshi Ozaki; Masatoshi Hori; Kazuya Kinoshita; Takashi Ohama
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

Review 8.  Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.

Authors:  D C Wilson; A G Thomas; N M Croft; E Newby; A K Akobeng; A Sawczenko; J M E Fell; M S Murphy; R M Beattie; B K Sandhu; S G Mitton; D Casson; M Elawad; R Heuschkel; H Jenkins; T Johnson; S Macdonald; S H Murch
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-02       Impact factor: 2.839

Review 9.  Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.

Authors:  Chinyu Su; Gary R Lichtenstein
Journal:  Gastroenterol Clin North Am       Date:  2004-06       Impact factor: 3.806

10.  Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration.

Authors:  E Bruzzese; V Raia; G Gaudiello; G Polito; V Buccigrossi; V Formicola; A Guarino
Journal:  Aliment Pharmacol Ther       Date:  2004-10-01       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.